Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System

NCT06146777 is registered in ClinicalTrials.gov with First Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT06146777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06146777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System
Lead sponsor
First Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 1, 2023
Completion date
December 1, 2030
Enrollment
468 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

papillary renal cell carcinoma